Is second-line systemic chemotherapy beneficial in patients with non-small cell lung cancer (NSCLC)? A multicenter data evaluation by the Anatolian Society of Medical Oncology

Basit Öğe Kaydı
dc.contributor.authorOdabas, Hatice
dc.contributor.authorUlas, Arife
dc.contributor.authorAydin, Kubra
dc.contributor.authorInanc, Mevlude
dc.contributor.authorAksoy, Asude
dc.contributor.authorYazilitas, Dogan
dc.contributor.authorTurkeli, Mehmet
dc.date.accessioned2024-04-24T16:10:36Z
dc.date.available2024-04-24T16:10:36Z
dc.date.issued2015
dc.departmentDicle Üniversitesien_US
dc.description.abstractPatients with advanced non-small cell lung cancer (NSCLC) generally require second-line treatment although their prognosis is poor. In this multicenter study, we aimed to detect the characteristics related to patients and disease that can predict the response to second-line treatments in advanced NSCLC. Data of 904 patients who have progressed after receiving first-line platinum-based chemotherapy in 11 centers with the diagnosis of stage IIIB and IV NSCLC and who were evaluated for second-line treatment were retrospectively analyzed. The role of different factors in determining the benefit of second-line treatment was analyzed. Median age of patients was 57 years (range 19-86). Docetaxel was the most commonly used (20.9 %, n = 189) single agent, while gemcitabine-platinum was the most commonly used (6.7 %, n = 61) combination chemotherapy regimen in second-line setting. According to survival analysis, median progression-free survival after first-line treatment (PFS2) was 3.5 months (standard error (SE) 0.2; 95 % confidence interval (CI), 3.2-3.9), median overall survival (OS) was 6.7 months (SE 0.3; 95 % CI, 6.0-7.3). In multivariate analysis, independent factors affecting PFS2 were found to be hemoglobin (Hb) level over 12 g/dl and treatment-free interval (TFI) longer than 3 months (p = 0.006 and 0.003, respectively). Similarly, in OS analysis, Hb level over 12 g/dl and time elapsed after the first-line treatment that is longer than 3 months were found to be independent prognostic factors (p = 0.0001 and 0.045, respectively). In light of these findings, determining and using the parameters for which the treatment will be beneficial prior to second-line treatment can increase success rate.en_US
dc.identifier.doi10.1007/s13277-015-3728-0
dc.identifier.endpage9648en_US
dc.identifier.issn1010-4283
dc.identifier.issn1423-0380
dc.identifier.issue12en_US
dc.identifier.pmid26150339
dc.identifier.scopus2-s2.0-84952876485
dc.identifier.scopusqualityQ3
dc.identifier.startpage9641en_US
dc.identifier.urihttps://doi.org/10.1007/s13277-015-3728-0
dc.identifier.urihttps://hdl.handle.net/11468/14941
dc.identifier.volume36en_US
dc.identifier.wosWOS:000367329300059
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherSage Publications Ltden_US
dc.relation.ispartofTumor Biology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectHemoglobin Levelen_US
dc.subjectNon-Small Cell Lung Canceren_US
dc.subjectSecond-Line Treatmenten_US
dc.subjectPrognostic Factorsen_US
dc.subjectSurvivalen_US
dc.titleIs second-line systemic chemotherapy beneficial in patients with non-small cell lung cancer (NSCLC)? A multicenter data evaluation by the Anatolian Society of Medical Oncologyen_US
dc.titleIs second-line systemic chemotherapy beneficial in patients with non-small cell lung cancer (NSCLC)? A multicenter data evaluation by the Anatolian Society of Medical Oncology
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu